在多发性骨髓瘤治疗中的单克隆抗体
Niels W C J van de Donk1, Sonja Zweegman1
1Department of Hematology, Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, Amsterdam 1081 HV, the Netherlands; Cancer Center Amsterdam, Cancer Biology and Immunology, Amsterdam, the Netherlands.
单克隆抗体显著改善多发性骨髓瘤 (MM) 治疗结果. 新的抗体疗法和施用方法为患有这种血液癌症的患者提供了更高的疗效和安全性.
科学领域:
- 血液学 血液学 血液学
- 免疫治疗是一种免疫疗法.
- 在瘤学瘤学.
背景情况:
- 单克隆抗体已经改变了多发性骨髓瘤 (MM) 治疗.
- 埃洛图祖马布与免疫调节药物在复发性/耐药性MM中显示出协同作用.
- 针对CD38的抗体,如达拉图穆马布和伊萨图西马布,提供单剂活性和良好的安全性.
研究的目的:
- 审查单克隆抗体在多发性骨髓瘤治疗中的作用和进展.
- 讨论基于抗体的治疗方案的疗效,安全性和未来方向.
主要方法:
- 对MM中单克隆抗体的临床结果的审查.
- 分析特定抗体 (埃洛图祖马布,达拉图穆马布,伊萨图キシ马布) 和它们的组合.
- 讨论给药途径和潜在的干扰.
主要成果:
- 单克隆抗体在新诊断和复发/耐药MM中显著改善了临床结果.
- 皮下注射减少了输液相关反应.
- 治疗性抗体可能会干扰完整反应评估.
结论:
- 单克隆抗体是现代MM治疗方案的组成部分.
- 下一代抗体正在开发中,以进一步改善患者的治疗结果.
- 优化抗体选择和管理是改善MM护理的关键.
更多相关视频
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
07:24Repression of Multiple Myeloma Cell Growth In Vivo by Single-wall Carbon Nanotube SWCNT-delivered MALAT1 Antisense Oligos
Published on: December 13, 2018
相关概念视频
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
